^
BIOMARKER:

APOBEC mutagenesis

APOBEC mutagenesis
Urothelial Cancer
atezolizumab
Sensitive: B - Late Trials
APOBEC mutagenesis
Urothelial Cancer
pembrolizumab
Sensitive: C3 – Early Trials
APOBEC mutagenesis
Urothelial Cancer
cisplatin
Resistant: C3 – Early Trials
APOBEC mutagenesis
Urothelial Cancer
carboplatin
Resistant: C3 – Early Trials